Siena, Italy

Aldo Tagliabue


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 59(Granted Patents)


Location History:

  • Pianella, IT (1988)
  • Siena, IT (1993)

Company Filing History:


Years Active: 1988-1993

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Aldo Tagliabue: Innovator in Synthetic Peptide Technology

Introduction

Aldo Tagliabue is a notable inventor based in Siena, Italy. He has made significant contributions to the field of synthetic peptides, holding 2 patents that focus on enhancing immune responses. His work is particularly relevant in the development of adjuvants for therapeutic applications.

Latest Patents

One of his latest patents is for a synthetic nonapeptide designed for use as an adjuvant. This specification relates to a synthetic peptide converted into a salt comprising one or more amine groups. It is capable of potentiating in vivo the primary and secondary antibody response to thymo-dependent and thymo-independent antigens that have low immunogenicity. Injectable preparations comprising a solution of the peptide in a pharmacologically acceptable solvent are particularly useful as adjuvants in therapy. Another significant patent is for a synthetic peptide with human interleukin 1 activity. This peptide can be used as a stimulant of immune functions and can be defined by a general formula.

Career Highlights

Aldo Tagliabue is associated with Sclavo Spa, a company known for its innovative approaches in the pharmaceutical industry. His work at Sclavo Spa has allowed him to focus on the development of cutting-edge therapeutic solutions.

Collaborations

Throughout his career, Aldo has collaborated with notable colleagues, including Guido Antoni and Diana Boraschi. These collaborations have further enriched his research and development efforts in the field of immunology.

Conclusion

Aldo Tagliabue's contributions to synthetic peptide technology highlight his role as an innovator in the pharmaceutical industry. His patents reflect a commitment to advancing therapeutic applications that enhance immune responses.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…